Half-life

1.1 h

Tmax

0.5 h

Category

peptide

Hexarelin is a hexapeptide GH secretagogue with high potency at GHS-R1a and additional reported activity at CD36 receptors. Preclinical studies have suggested cardiovascular signalling effects distinct from its GH-releasing action, including inotropic and cardioprotective properties in animal models. Its half-life is approximately 1 hour. While widely used in research, human data remain limited. Any user experimenting with hexarelin should meticulously document dosing, cardiac symptoms, and GH-related effects.

Mechanism

A synthetic hexapeptide growth-hormone secretagogue and ghrelin receptor agonist. Research has also explored possible cardiac-related signaling independent of growth-hormone release; human mechanistic data are limited.

Research summary

Studied as a potent growth-hormone secretagogue in early clinical and preclinical work. It is not an FDA-approved therapeutic, and long-term human outcome data are limited.

Reported side effects

Reported effects include injection-site reactions and possible desensitization of the growth-hormone response with continued use. Effects on growth hormone and IGF-1 warrant monitoring. The full profile is not established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Hexarelin growth-hormone and cardiovascular research · peer-reviewed endocrinology journals (1998)search PubMed for hexarelin growth hormone
Growth hormone secretagogue reviews · peer-reviewed review articles (2015)class context

References

Hexarelin reviewDOI: 10.1016/j.peptides.2010.10.011

A TrackPep egy naplózó alkalmazás. Azt rögzíti, amit megadsz, és soha nem javasol vagy számít ki mennyiségeket.